This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory



CSL Announces Site for Longer-Acting Recombinant FIX Study

CSL Behring has announced that Vienna, Austria, will be the first site initiated in its global phase II/III, multi-center study to evaluate the safety, efficacy and pharmacokinetics of its recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The prospective, open-label study will enroll adolescents and adults (12-65 years of age) with hemophilia B. CSL Behring is working in collaboration with its parent company, CSL Limited, to develop rIX-FP for the prophylactic treatment of bleeding episodes in patients with hemophilia B.


The new site is part of the PROLONG-9FP clinical study program, which has established study sites in seven other countries. CSL also announced that additional trial sites will be established in Japan, Russia and the U.S. later this year.


“The unmet medical need is great for a factor IX product with an extended half-life for use in treating people with hemophilia B, a life-long, debilitating clotting disorder,” said Russell Basser, MD, Senior Vice President, Global Clinical R&D at CSL Behring. “Such a therapy can mean fewer injections for patients, and may enable or enhance prophylactic treatment. This would be an improved convenience that may result in a better quality of life for patients.”


Source: CSL Behring news release dated January 12, 2012